Reflecting on the Data Pool: Emerging Roles for SGLT1 and SGLT2 Inhibition in T1DM
Strong evidence supports the importance of maintaining blood glucose levels as close to normal as possible in patients with type 1 diabetes mellitus (T1DM) to avoid or delay complications and reduce premature mortality. However, a high proportion of patients with T1DM in the United States have difficulty achieving recommended blood glucose goals. As those with T1DM must rely primarily on insulin to achieve glycemic control, there exists an unmet need for adjunct interventions to help people with T1DM address clinical challenges and overcome barriers to optimal glycemic control. Accordingly, healthcare professionals (HCPs) should be aware of new therapies that have demonstrated benefits in clinical trials and be prepared to use them as they become available. Hence, HCPs need to be familiar with data on the use of sodium glucose cotransporter (SGLT) 2 inhibitors and dual SGLT1/SGLT2 inhibitors for treating T1DM.
This activity has been developed to critically assess clinical evidence on the use of SGLT 2 and dual SGLT1/SGLT2 inhibitors for the management of T1DM. Based on a live symposium presented in conjunction with the American Association of Clinical Endocrinologists (AACE) 27th Annual Scientific & Clinical Congress in Boston, Massachusetts, on May 17, 2018, this activity is modeled after an academic journal club format. It presents reviews of and faculty commentary on selected studies (published before April 30, 2018) that investigated the efficacy and safety of SGLT2 or dual SGLT1/SGLT2 inhibitors in advanced development (phase 3 clinical trials or later) for the management of T1DM.
Please Note: this course is housed on CaringForDiabetes.com. Upon selecting 'Take Course,' you will be redirected to register and to complete the activity.
This activity is intended for endocrinologists and other endocrinology HCPs who provide diabetes support and education for patients with T1DM.
At the conclusion of this activity, participants will be able to:
- Describe the rationale for SGLT1 and SGLT2 inhibition as adjunct approaches to insulin for the treatment of T1DM
- Assess the strengths, weaknesses, and clinical relevance of key studies focused on the efficacy and safety of SGLT1 and SGLT2 inhibition for the treatment of T1DM
- Evaluate the potential impact of SGLT1 and SGLT2 inhibition on complications of T1DM, especially cardiovascular disease and renal impairment
Robert R Henry, MD—Program Chair
Professor of Medicine
University of California, San Diego
Chief, Section of Endocrinology, Metabolism & Diabetes
Veterans Affairs Healthcare System
San Diego, California
Paresh Dandona, MD, PhD
SUNY Distinguished Professor
Head, Division of Endocrinology, Diabetes & Metabolism
State University of New York at Buffalo
Buffalo, New York
Satish K Garg, MD
Editor-in-Chief, Diabetes Technology & Therapeutics
Professor of Medicine and Pediatrics
Garg Endowed Chairs and Director, Adult Clinic
Barbara Davis Center for Diabetes
The American Association of Clinical Endocrinologists (AACE) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The American Association of Clinical Endocrinologists (AACE) designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.